Nephrotic syndrome in relation to treatment with ustekinumab

Fernández, María Pérez; Bermejo, Ana Belén Piteiro; Esparragoza, J.K. Peña; Martínez, Ana Blasco; Moreno, Irene Aracil; Ramos, J. Mancha; Barrio, Fuensanta Moreno

doi:10.1016/j.nefroe.2018.06.016

Cited by 5 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 78 Ustekinumab, an anti-interleukin (anti-IL)-23 biologic is another option for moderate to severe UC and CD, but may be associated with nephrotic syndrome secondary to focal segmental glomerulosclerosis. 79 However, a recent real-world study was reassuring, with no renal complications described. 80 Tofacitinib was the first oral Janus kinase (JAK) inhibitor approved for the treatment of UC.…”

Section: Drug-related Nephrotoxicitymentioning

confidence: 99%

Renal and Urological Disorders Associated With Inflammatory Bowel Disease

Kumar

Pollok

Goldsmith

2022

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Renal and urinary tract complications related to inflammatory bowel disease (IBD) have been relatively understudied in the literature compared with other extraintestinal manifestations. Presentation of these renal manifestations can be subtle, and their detection is complicated by a lack of clarity regarding the optimal screening and routine monitoring of renal function in IBD patients. Urolithiasis is the most common manifestation. Penetrating Crohn’s disease involving the genitourinary system as an extraintestinal complication is rare but associated with considerable morbidity. Some biologic agents used to treat IBD have been implicated in progressive renal impairment, although differentiating between drug-related side effects and deteriorating kidney function due to extraintestinal manifestations can be challenging. The most common findings on renal biopsy of IBD patients with renal injury are tubulointerstitial nephritis and IgA nephropathy, the former also being associated with drug-induced nephrotoxicity related to IBD medication. Amyloidosis, albeit rare, must be diagnosed early to reduce the chance of progression to renal failure. In this review, we evaluate the key literature relating to renal and urological involvement in IBD and emphasize the high index of suspicion required for the prompt diagnosis and treatment of these manifestations and complications, considering the potential severity and implications of acute or chronic loss of renal function. We also provide suggestions for future research priorities.

show abstract

Section: Drug-related Nephrotoxicitymentioning

confidence: 99%